A Phase 1, Open-label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-993 Following Single Oral Administration in Healthy Subjects
Latest Information Update: 23 Apr 2025
At a glance
- Drugs VX 993 (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 18 Apr 2025 Status changed from not yet recruiting to recruiting.
- 24 Mar 2025 New trial record